The Discovery and Development of Cisplatin 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 1725
Special Issue Editor
Interests: ototoxicity; hearing loss; cisplatin; nanoparticles; regenerative medicine in otorhinolaryngology; decellularization
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cisplatin (cis-diamminedichloroplatinum (II)) is one of the most widely used chemotherapies worldwide. It was first synthesized in 1844 by the Italian chemist Michele Peyrone (1813–1883), but it was only in 1965 that it was accidentally identified as an anticancer agent by the biophysical chemist Barnett Rosenberg (1926–2009). In 1978, it was approved by the US Food and Drug Administration (FDA) as an anticancer treatment for patients with testicular and bladder cancer. Since then, cisplatin has been used to treat many neoplasms affecting several millions of patients as part of an approved therapeutic regimen or clinical study.
This Special Issue seeks to provide a roundtable where researchers with different backgrounds can contribute their findings to this highly relevant field. Therefore, the scope of the Issue encompasses, but is not restricted to, the following areas: the unexpected events leading the discovery of cisplatin’s antitumor action, its introduction to clinical practice, the comprehension of its mechanism of action and the ongoing research to overcome cisplatin resistance. The use of cisplatin is associated with numerous side effects, including nephrotoxicity, neurotoxicity and ototoxicity. Nephrotoxicity may be reduced or prevented by intravenous hydration, while neurotoxicity and ototoxicity are still lacking therapeutic and preventive treatments. Despite the success of cisplatin in cancer therapy, extensive research efforts have been devoted to improving the cisplatin formula, aiming to limit adverse events. Therefore, contributions to this Issue in the forms of both original research and review articles could cover any aspect of the development of new platinum-based strategies maintaining anticancer activity and simultaneously avoiding known side effects.
Dr. Erica Gentilin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cisplatin
- cisplatin synthesis
- mechanism of action
- anticancer drugs
- drug resistance
- side effects
